SLC19A1 and psoriasis: The SLC19A1 rs1051266 polymorphism (G>A) results in a histidine-to-arginine substitution that may reduce transporter affinity for MTX, potentially leading to decreased intracellular accumulation and diminished efficacy, as supported by previous pharmacogenetic investigations in rheumatoid arthritis and psoriasis [25,26].